Gareth J. Morgan mostly deals with Multiple myeloma, Internal medicine, Surgery, Oncology and Bone marrow. His study focuses on the intersection of Multiple myeloma and fields such as Cancer research with connections in the field of Natural killer cell. The various areas that he examines in his Internal medicine study include Gastroenterology and Pathology.
In general Surgery study, his work on Autologous stem-cell transplantation, Melphalan, Zoledronic acid and Autologous transplantation often relates to the realm of Clodronic acid, thereby connecting several areas of interest. The study incorporates disciplines such as Context, Survival rate, Cyclophosphamide, Retrospective cohort study and Hazard ratio in addition to Oncology. His Bone marrow research is included under the broader classification of Immunology.
Internal medicine, Multiple myeloma, Oncology, Immunology and Surgery are his primary areas of study. His Internal medicine research includes themes of Gastroenterology and Cardiology. His Multiple myeloma research is multidisciplinary, incorporating perspectives in Cancer research and Bone marrow, Pathology.
His studies in Oncology integrate themes in fields like Cancer, Clinical trial, Bioinformatics and Dexamethasone. His Immunology research is mostly focused on the topic Antibody. His Thalidomide research integrates issues from Regimen, Cyclophosphamide, Maintenance therapy and Melphalan.
His primary scientific interests are in Internal medicine, Multiple myeloma, Oncology, Cardiology and Cancer research. His studies in Lenalidomide, Transplantation, Progression-free survival, Thalidomide and Cyclophosphamide are all subfields of Internal medicine research. His Multiple myeloma research includes elements of Monoclonal gammopathy of undetermined significance, Computational biology, Bone marrow and Disease.
His Computational biology study combines topics from a wide range of disciplines, such as Gene and Whole genome sequencing. Gareth J. Morgan regularly ties together related areas like Cancer in his Bone marrow studies. His studies examine the connections between Oncology and genetics, as well as such issues in Clinical trial, with regards to Randomized controlled trial.
His primary areas of investigation include Multiple myeloma, Internal medicine, Oncology, Transplantation and Cardiology. His Multiple myeloma research incorporates elements of Survival rate, Cancer research, Maintenance therapy and Bone marrow. His biological study spans a wide range of topics, including Cancer, Genetic heterogeneity, Gene signature and Mesenchymal stem cell.
Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Gastroenterology. His study in Oncology is interdisciplinary in nature, drawing from both Risk stratification, Proportional hazards model and MEDLINE. Gareth J. Morgan has researched Lenalidomide in several fields, including Thalidomide and Bortezomib.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
International uniform response criteria for multiple myeloma
B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade.
International staging system for multiple myeloma.
Philip R. Greipp;Jesus San Miguel;Brian G.M. Durie;John J. Crowley.
Journal of Clinical Oncology (2005)
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie.
British Journal of Haematology (2003)
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.
J J M van Dongen;A W Langerak;M Brüggemann;P A S Evans.
High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.
J. Anthony Child;Gareth J. Morgan;Faith E. Davies;Roger G. Owen.
The New England Journal of Medicine (2003)
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst.
Journal of Clinical Oncology (2015)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Faith E. Davies;Faith E. Davies;Faith E. Davies;Noopur Raje;Noopur Raje;Noopur Raje;Teru Hideshima;Teru Hideshima;Teru Hideshima;Suzanne Lentzsch;Suzanne Lentzsch;Suzanne Lentzsch.
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.
R Fonseca;P L Bergsagel;J Drach;J Shaughnessy.
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel.
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: